What is CAPR (CAPR) stock price today?

CAPR (CAPR) is currently trading at $10.01, up 1.01% today.

What is CAPR P/E ratio?

CAPR's P/E ratio is -4.01. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CAPR return on equity (ROE)?

CAPR's return on equity (ROE) is -56.60%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is CAPR's market cap?

CAPR has a market capitalization of $575.68M.

NASDAQ · Biotechnology

CAPR (CAPR) Stock

$10.01 +1.01% NASDAQ: CAPR Healthcare

Valuation

Metric	Value
Price	$10.01
Market Cap	$575.68M
P/E Ratio	-4.01
P/B Ratio	2.31
P/S Ratio	81.76
EPS (TTM)	$-2.26
52-Week High	$40.37
52-Week Low	$2.96
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-56.60%
ROA	-35.10%
ROCE	-40.25%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.37
Current Ratio	9.01

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$3.0M	$25.0M	$22.0M	$0
Operating Profit	$-21.0M	$-30.0M	$-24.0M	$-43.0M	$-108.0M
Net Profit	$-20.0M	$-29.0M	$-22.0M	$-40.0M	$-105.0M
EPS	$-0.87	$-1.18	$-0.83	$-1.15	$-2.26
Op Margin	-8549.9%	-1163.9%	-95.6%	-191.1%	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$41.0M	$50.0M	$59.0M	$170.0M	$356.0M
Total Liabilities	$10.0M	$38.0M	$36.0M	$25.0M	$50.0M
Cash	$35.0M	$10.0M	$15.0M	$11.0M	$288.0M
Borrowings	$6.0M	$6.0M	$6.0M	$5.0M	$18.0M

Latest News

CAPR Stock Hits Over 4-Month Low: Capricor Execs Cash In $1.5M As FDA Sets Stage For DMD Drug Review Stocktwits · Jun 30, 2026 Capricor Therapeutics Gets FDA Advisory Panel Meeting for Duchenne Therapy MT Newswires · Jun 29, 2026 Capricor’s Positive 5-Year Data For DMD Treatment Comes With A Regulatory Catch – CAPR Stock Slides 11% Stocktwits · Jun 26, 2026 Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy GlobeNewswire · Jun 26, 2026 Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference GlobeNewswire · Jun 26, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-17.0M	$5.0M	$-26.0M	$-40.0M	$-70.0M
Investing Cash Flow	$-2.0M	$-38.0M	$3.0M	$-118.0M	$95.0M
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$2.0M	$-25.0M	$5.0M	$-3.0M	$277.0M
Free Cash Flow	$-18.0M	$2.0M	$-28.0M	$-42.0M	$-73.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.10
EV / EBITDA	0.54
FCF Yield	-23.00%
Quick Ratio	7.35
Interest Coverage	-44.38
Return 1Y	190.76%
Return 3Y	338.72%
Return 5Y	377.60%

Ownership

Insiders Held9.47%

Institutions Held59.73%

Institutions Float Held65.98%

Institutional Holder	Shares	Report Date
Suvretta Capital Management, LLC	3,818,600	2026-03-31
Blackrock Inc.	3,421,815	2026-03-31
Tang Capital Management, LLC	3,399,900	2026-03-31
State Street Corporation	2,181,901	2026-03-31
Vanguard Capital Management LLC	2,027,732	2026-03-31

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACHV	$8.25	+3.90%	-4.63	$846.94M	0.00%
ALLO	$1.99	-0.75%	-2.17	$685.13M	0.00%
ARCT	$16.23	+9.93%	-2.93	$461.16M	0.00%
CABA	$3.30	+6.11%	-2.23	$538.08M	0.00%
EDIT	$3.07	+0.33%	-1.39	$471.13M	0.00%

About CAPR

CAPR is led by CEO Linda Marbán, employs 160 people, headquartered in US, publicly traded since 2007.

CAPR stock trades at $10.01 with a market capitalization of $575.68M. The stock is valued at a price-to-earnings (P/E) ratio of -4.01, price-to-book of 2.31, price-to-sales of 81.76. Over the past 52 weeks the stock has ranged between $2.96 and $40.37, and currently trades 75.2% below its 52-week high.

On profitability, CAPR generates a return on equity (ROE) of -56.60%, return on capital employed of -40.25%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides